Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial
Aumolertinib plus chemotherapy shows potential as first-line treatment for patients with EGFR-mutant advanced NSCLC, which deserves to be investigated in randomized controlled trials. CtDNA clearance may be a prognostic marker.
Authors
- Zhanyu Pan (ORCID: https://orcid.org/0000-0002-8447-0119)
- Feng He (ORCID: https://orcid.org/0000-0001-8359-2635)
- Yong Li (ORCID: https://orcid.org/0000-0002-8910-9787)
- Chenguang Li (ORCID: https://orcid.org/0000-0002-5287-5269)
- Yanwei Li (ORCID: https://orcid.org/0000-0003-3828-9754)
- Xiaoliang Zhao (ORCID: https://orcid.org/0000-0001-8787-076X)
Institutions
- Tianjin University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- National Clinical Research (US)
- Tianjin Medical University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1093/oncolo/oyae336
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Tianjin Municipal Health Commission